Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer News-Medical.net The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. ... "This is the ... |
